<DOC>
	<DOCNO>NCT01211561</DOCNO>
	<brief_summary>Selenium 's ability prevent colorectal cancer ( CRC ) suspect nearly 30 year , never directly study human . The investigator directly assess selenium 's ability prevent CRC measuring alteration aberrant crypt focus ( ACF ) , accept surrogate marker CRC . ACF 's small ( i.e. , microscopic ) collection abnormally shape cell commonly use marker CRC risk . Screening colonoscopy UIC routinely use method allow ACF count do part standard practice . ACF 's fix , like polyp cancer , disappear person 's risk develop CRC decrease . The investigator propose give patient 's 6 ACF 's 200 mcg selenized yeast placebo , determine drug-dependant decrease ACF number . The primary objective determine whether selenized yeast supplementation , compare placebo , cause significant reduction ACF number baseline level . The primary endpoint change ACF number</brief_summary>
	<brief_title>Colon Cancer Prevention Using Selenium</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Selenium</mesh_term>
	<criteria>All nonpregnant patient &gt; 50 year age The follow specifically look , result patient eligible study enrollment : Use nonsteroidal antiinflammatory drug glucocorticosteroids within 60 day study entry . History chronic IBD prior pelvic radiation ( inflammation distort crypt pattern ) . Intake selenium supplement within 60 day study entry , include vitamin . Patients increase bleed risk biopsy protocol ( i.e . renal failure , decompensated cirrhosis , blood dyscrasia ) .</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2010</verification_date>
</DOC>